Chemotherapy-induced tumor gene expression changes in human breast cancers

Pharmacogenetics and Genomics

Volumn 19, Issue 3, 2009, Pages 181-192

  Lee, Soo Chin ^a,b   Xu, Xin ^a   Lim, Yi Wan ^a   Lau, Philip ^b   Sukri, Norita ^a   Lim, Siew Eng ^a   Yap, Hui Ling ^a   Yeo, Wee Lee ^a   Tan, Patrick ^c   Tan, Sing Huang ^a   McLeod, Howard ^d   Goh, Boon Cher ^a  

^a Department of Haematology Oncology ^*  (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Doxorubicin; Drug resistance; Gene expression

Indexed keywords

ACTIN; CELL ADHESION MOLECULE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

ARTICLE; BREAST CANCER; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FOCAL ADHESION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GENE; UNINDEXED SEQUENCE; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; TAXOIDS;

EID: 62349119652     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32831ebb5d     Document Type: Article

References (28)

1. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362:362-369.
2. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22:2284-2293.
3. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23:422-431.
4. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24:1839-1845.
5. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34:85-90.
6. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002; 8:461-468.
7. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23:3331-3342.
8. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004; 10:6418-6431.
9. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Institute 2007; 99:147-157.
10. Kamada T, Kawai S. An algorithm for drawing general undirected graphs. Inf Processing Lett 1989; 31:7-15.
11. Batagelj V, Mrvar A. Pajek-analysis and visualization of large networks. In: Junger M, Mutzel P, editors. Graph drawing software. Berlin: Springer; 2003, pp. 77-103.
12. Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environ Health Perspect 2004; 112:1607-1613.
13. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006; 5:2914-2918.
14. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001; 98: 11462-11467.
15. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12:1294-1300.
16. Takeuchi K, Motoda Y, Ito F. Role of transcription factor activator protein 1 (AP1) in epidermal growth factor-mediated protection against apoptosis induced by a DNA-damaging agent. FEBS J 2006; 273:3743-3755.
17. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating surviving gene expression. J Biol Chem 2006; 281:25903-25914.
18. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, et al. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 2004; 22:248-256.
19. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002; 98:463-469.
20. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94:1604-1609.
21. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976-10983.
22. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23:1169-1177.
23. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007; 9:R37.
24. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics Genomics 2007; 17:813-826.
25. Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005; 11:6226-6232.
26. Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG, et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 2004; 64:8357-8364.
27. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994; 54:5255-5257.
28. Webber MM, Rehman SM, James GT. Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. Cancer Res 1988; 48:4503-4508.